WP
AVDL

Woodline Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Woodline Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-702,066
Closed -$15.1M – 1033
2025
Q4 		$15.1M Sell
702,066
-195,020
-22% -$3.79M 0.06% 369
2025
Q3 		$13.7M Hold
897,086
– – 0.06% 364
2025
Q2 		$7.94M Buy
897,086
+225
+0% +$1.98K 0.04% 474
2025
Q1 		$7.02M Buy
896,861
+395,040
+79% +$3.31M 0.05% 426
2024
Q4 		$5.27M Sell
501,821
-1,185,492
-70% -$14.4M 0.04% 477
2024
Q3 		$22.1M Buy
1,687,313
+182,781
+12% +$2.78M 0.19% 179
2024
Q2 		$21.2M Buy
1,504,532
+4,008
+0.3% +$65.3K 0.2% 158
2024
Q1 		$25.3M Sell
1,500,524
-351,888
-19% -$5.24M 0.23% 140
2023
Q4 		$26.2M Sell
1,852,412
-50,431
-3% -$592K 0.28% 111
2023
Q3 		$19.6M Buy
1,902,843
+23,500
+1% +$315K 0.23% 134
2023
Q2 		$31M Hold
1,879,343
– – 0.37% 74
2023
Q1 		$17.2M Buy
1,879,343
+1,266,202
+207% +$10.4M 0.23% 122
2022
Q4 		$4.39M Buy
613,141
+516,235
+533% +$3.62M 0.06% 339
2022
Q3 		$485K Sell
96,906
-1,488,386
-94% -$8.19M 0.01% 596
2022
Q2 		$3.87M Sell
1,585,292
-530,737
-25% -$2.18M 0.06% 299
2022
Q1 		$14.5M Sell
2,116,029
-146,973
-6% -$1.01M 0.23% 129
2021
Q4 		$18.3M Buy
2,263,002
+535,942
+31% +$4.9M 0.26% 116
2021
Q3 		$16.9M Buy
1,727,060
+1,494,523
+643% +$11.8M 0.28% 103
2021
Q2 		$1.56M Buy
+232,537
New +$1.85M 0.03% 382

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Woodline Partners's AVDL Position: Q1 2026 in Review

Woodline Partners sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 702,066 shares — an estimated $15.1M sold.

Woodline Partners first reported a position in AVDL in Q2 2021 and held it in 19 quarters. The position peaked at $31M in Q2 2023. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Woodline Partners reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Woodline Partners sold 702,066 Avadel Pharmaceuticals shares in Q1 2026, an estimated $15.1M.
  • Woodline Partners first reported a position in Avadel Pharmaceuticals in Q2 2021 and held it in 19 quarters.
  • Woodline Partners's Avadel Pharmaceuticals position peaked at $31M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.